Savara Inc.

NasdaqGS:SVRA 주식 보고서

시가총액: US$576.6m

Savara 관리

관리 기준 확인 2/4

Savara CEO는 Matt Pauls, Sep2020 에 임명되었습니다 의 임기는 4.17 년입니다. 총 연간 보상은 $ 3.76M, 15.8% 로 구성됩니다. 15.8% 급여 및 84.2% 보너스(회사 주식 및 옵션 포함). 는 $ 1.71M 가치에 해당하는 회사 주식의 0.3% 직접 소유합니다. 1.71M. 경영진과 이사회의 평균 재임 기간은 각각 3.2 년과 7.6 년입니다.

주요 정보

Matt Pauls

최고 경영자

US$3.8m

총 보상

CEO 급여 비율15.8%
CEO 임기4.2yrs
CEO 소유권0.3%
경영진 평균 재임 기간3.2yrs
이사회 평균 재임 기간7.6yrs

최근 관리 업데이트

Recent updates

Savara: Trial Successful, But I'm Only Half Convinced

Sep 09

Savara: Today's Data 'Win' Rouses Market All Too Briefly

Jun 26

Savara: The Binary Bet On Phase 3 Data

Jun 07

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

Dec 14
Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Feb 16
Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Oct 12
Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Aug 26

Savara GAAP EPS of -$0.06 in-line

Aug 11

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Jan 24
Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Is Savara (NASDAQ:SVRA) A Risky Investment?

Jul 05
Is Savara (NASDAQ:SVRA) A Risky Investment?

Savara: They Failed Once, But They Are Trying Again

Jun 07

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Mar 17
The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Feb 26
Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex

Nov 24

Savara EPS misses by $0.01

Nov 05

CEO 보상 분석

Matt Pauls 의 보수는 Savara 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$83m

Jun 30 2024n/an/a

-US$75m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$4mUS$595k

-US$55m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$43m

Mar 31 2023n/an/a

-US$40m

Dec 31 2022US$2mUS$580k

-US$38m

Sep 30 2022n/an/a

-US$39m

Jun 30 2022n/an/a

-US$39m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$2mUS$560k

-US$43m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$46m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$2mUS$170k

-US$50m

Sep 30 2020n/an/a

-US$68m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$81m

Dec 31 2019US$64kn/a

-US$78m

Sep 30 2019n/an/a

-US$57m

Jun 30 2019n/an/a

-US$57m

Mar 31 2019n/an/a

-US$47m

Dec 31 2018US$114kn/a

-US$62m

Sep 30 2018n/an/a

-US$58m

Jun 30 2018n/an/a

-US$52m

Mar 31 2018n/an/a

-US$53m

Dec 31 2017US$75kn/a

-US$31m

보상 대 시장: Matt 의 총 보상 ($USD 3.76M )은 US 시장( $USD 2.14M ).

보상과 수익: 회사가 수익성이 없는 동안 Matt 의 보상이 증가했습니다.


CEO

Matt Pauls (53 yo)

4.2yrs

테뉴어

US$3,759,723

보상

Mr. Matthew Pauls, J.D. M.B.A. also known as Matt, is Director at NVN Liquidation Inc. He serves as Director of Soleno Therapeutics, Inc. since August 15, 2023 and is its Lead Independent Director aince Au...


리더십 팀

이름위치테뉴어보상소유권
Matthew Pauls
Chairman & CEO4.2yrsUS$3.76m0.30%
$ 1.7m
David Lowrance
CFO, Chief Administrative Officer & Secretary8yrsUS$1.52m0.048%
$ 276.7k
Robert Lutz
Chief Operating Officer1.8yrsUS$2.66m0%
$ 0
Kate McCabe
Senior VP & General Counsel6.7yrs데이터 없음데이터 없음
Anne Erickson
Chief Business Officer4.1yrs데이터 없음0.069%
$ 396.3k
Brian Maurer
Head of Clinical Operations3.5yrs데이터 없음데이터 없음
Charles LaPree
Senior Vice President of Global Regulatory Affairs & Quality Assurance3.3yrs데이터 없음데이터 없음
Peter Clarke
Executive Vice President of Global Technical Operations3.2yrs데이터 없음데이터 없음
Raymond Pratt
Chief Medical Officer2yrsUS$698.69k0.064%
$ 369.7k
Scott Wilhoit
Executive Vice President of Global Commercial1.8yrs데이터 없음데이터 없음
Brian Robinson
Senior VP of Global Medical Affairs1.6yrs데이터 없음데이터 없음
Yasmine Wasfi
Executive VP and Head of Clinical Development & Clinical Operationsless than a year데이터 없음데이터 없음

3.2yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: SVRA 의 관리팀은 경험 ( 3.2 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Matthew Pauls
Chairman & CEO7.6yrsUS$3.76m0.30%
$ 1.7m
David Ramsay
Independent Director7.6yrsUS$158.13k1.35%
$ 7.8m
Joseph S. McCracken
Lead Independent Director11.1yrsUS$155.13k0.11%
$ 632.8k
Richard Hawkins
Independent Director14.1yrsUS$149.13k0.0074%
$ 42.8k
Nevan Elam
Independent Director15.8yrsUS$157.63k0%
$ 0
Bruce Trapnell
Member of Clinical Advisory Boardno data데이터 없음데이터 없음
Francesco Bonella
Member of Clinical Advisory Boardno data데이터 없음데이터 없음
Yoshikazu Inoue
Member of Clinical Advisory Boardno data데이터 없음데이터 없음
An van Es-Johansson
Independent Director4.9yrsUS$155.63k0%
$ 0
Cormac McCarthy
Member of Clinical Advisory Board3.8yrs데이터 없음데이터 없음
Tisha Wang
Member of Clinical advisory Board1.8yrs데이터 없음데이터 없음

7.6yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 이사회: SVRA 의 이사회경험(평균 재직 기간 7.6 년)으로 간주됩니다.